Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-121 in Relapsed/Refractory Hematologic Malignancies
NCT05908409Phase 2Recruiting
- Sponsor
- IDP Discovery Pharma
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of IDP-121 in multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), chronic lymphocytic leukemia (CLL), sponsored by IDP Discovery Pharma. Started Jun 2023; status: recruiting.
02
Drugs
IDP-121
03
Conditions
multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05908409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908409.